You will now be redirected to the GD3 website
Genesis Drug Discovery & Development is a proud member of Genesis Drug Discovery & Development (GD3), a fully integrated CRO providing services to support drug discovery programs of our clients from target discovery through IND filing and managing Phase I-III clinical trials.
Learn more about GD3News
-
June 13, 2024
Exhibitor at the ASM-Microbe 2024 Conference in Atlanta, GA
June 13-17 -
May 9, 2024
Exhibitor at the ARVO 2024 Vision for the Future Conference in Seattle, WA
May 5-9 -
March 10, 2024
Exhibitor at the Society of Toxicology (SOT) 63rd Annual Meeting and ToxExpo in Salt Lake City, Utah
March 10–14 -
May 10, 2023
Genesis Drug Discovery & Development (GD3), a member of Genesis Global Group, acquires JSS Medical Research to expand its clinical services portfolio.
Read More -
January 10, 2023
Genesis Axis Acquires Organochem to Grow the Preclinical Chemistry Services Portfolio.
Read More -
October 7, 2021
Genesis Biotechnology Group Acquires BioBlocks to Grow the Preclinical Chemistry Services Portfolio of Genesis Drug Discovery & Development (GD3)
Read More -
March 4, 2021
Genesis Drug Discovery and Development acquires Integrated Analytical Solutions to add “off the shelf” PK profiling capabilities to its portfolio
Read More -
January 6, 2021
Genesis Drug Discovery and Development expands its presence in the clinical space by acquiring STATKING Clinical Services
Read More -
September 16, 2020
Genesis Drug Discovery & Development Appoints Laura Sailor Veteran CRO Business Development Leader as Director of Business Development
Read More -
September 16, 2020
Genesis Drug Discovery & Development Appoints Anthony Rohr as Chief Operating Officer
Read More -
August 4, 2020
Genesis Drug Discovery & Development (GD3) Announces Appointment of Anthony Rohr, as Chief Executive Officer of PharmOptima
Read More -
November 19, 2019
Genesis Biotechnology Group acquires NEDP to grow the Preclinical Chemistry services portfolio of Genesis Drug Discovery & Development (GD3)
Read More -
June 18, 2019
Genesis Drug Discovery & Development Expands Preclinical Contract Research Portfolio by Acquiring NexusPharma
Read More -
February 27, 2019
Genesis Drug Discovery & Development Announces Operating Agreement with Ophthy-DS, Inc.
Read More -
July 19, 2018
Genesis Drug Discovery & Development Appoints Olesia Buiakova, M.D., Ph.D., as Chief Scientific Officer
Read More -
March 1, 2017
Genesis Biotechnology Group Expands Preclinical Contract Research Portfolio by Acquiring PharmOptima
Read More